Zoetis (ZTS) Given Daily Media Impact Rating of 0.18
News stories about Zoetis (NYSE:ZTS) have trended somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Zoetis earned a coverage optimism score of 0.18 on Accern’s scale. Accern also gave headlines about the company an impact score of 47.0114236700552 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Zoetis Inc. (ZTS): Are There Still Some Opportunities On The Horizon – StockNewsGazette (stocknewsgazette.com)
- Ford Focus cars being recalled with a potential fuel tank fault (fishinghd.com)
- First Bank & Trust Purchases Shares of 9106 Zoetis Inc. (NYSE:ZTS) (expressnewsline.com)
- Watch for Zoetis Inc to Potentially Pullback After Gaining 1.50% Yesterday (mysmartrend.com)
- Zoetis Inc. (ZTS) registers a price change of -0.02% while Zynerba Pharmaceuticals, Inc. (ZYNE) finishes with a flow … – Stocks Gallery (stocksgallery.com)
ZTS has been the topic of several recent analyst reports. Deutsche Bank AG restated a “buy” rating and set a $65.00 price objective (up from $62.00) on shares of Zoetis in a research note on Monday, July 17th. BMO Capital Markets reiterated a “buy” rating and issued a $60.00 price target on shares of Zoetis in a research note on Thursday, May 4th. Zacks Investment Research upgraded shares of Zoetis from a “hold” rating to a “buy” rating and set a $67.00 price target on the stock in a research note on Wednesday, May 10th. Argus reiterated a “buy” rating and issued a $69.00 price target (up previously from $60.00) on shares of Zoetis in a research note on Tuesday, May 30th. Finally, Hilliard Lyons initiated coverage on shares of Zoetis in a research note on Tuesday, June 20th. They issued a “buy” rating and a $77.00 price target on the stock. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $64.78.
Zoetis (NYSE:ZTS) traded down 0.25% during mid-day trading on Friday, reaching $60.75. 1,513,092 shares of the company’s stock were exchanged. The company has a 50-day moving average of $61.95 and a 200-day moving average of $58.24. The stock has a market cap of $29.71 billion, a price-to-earnings ratio of 34.34 and a beta of 1.02. Zoetis has a 52-week low of $46.86 and a 52-week high of $63.85.
Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, August 8th. The company reported $0.53 earnings per share for the quarter, hitting the consensus estimate of $0.53. The firm had revenue of $1.27 billion during the quarter, compared to the consensus estimate of $1.27 billion. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The company’s revenue was up 5.0% on a year-over-year basis. During the same quarter last year, the company earned $0.49 earnings per share. Equities research analysts anticipate that Zoetis will post $2.34 earnings per share for the current year.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.